MedTrace Logo

Effects of Aminocaproic Acid (ACA) on Rosacea-specific Inflammation

NCT01398280 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2019-09-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effect of topical aminocaproic acid on the immune system by assessing the levels of antimicrobial peptides in the skin of patients with rosacea. It is hypothesized that aminocaproic acid applied topically will alter the body's immune system in patients with rosacea by inhibiting activation of antimicrobial peptides.

Conditions

  • Rosacea

Interventions

DRUG

Topical aminocaproic acid (ACA) mixed with Vanicream

25% Aminocaproic acid cream twice daily for up to 12 weeks.

DRUG

Vehicle cream

Vehicle cream moisturizer twice daily for up to 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Tissa Hata, MD · University of California, San Diego

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01398280 on ClinicalTrials.gov